News Releases

Allon completes U.S. $10 million financing agreement with Nordic Biotech entity

VANCOUVER, B.C.— November 1, 2010— Allon Therapeutics Inc. (TSX: NPC) (TSX: NPC) announced today it has closed a financing agreement with Isar Pharma K/S (“Isar”), a wholly owned limited partnership of Nordic Biotech Venture Fund II K/S under which Allon has received U.S. $10 million to advance ... Continue reading →

Pilot clinical trial meets primary endpoint with Allon’s davunetide

VANCOUVER, B.C.— October 8, 2010— Allon Therapeutics Inc. (TSX: NPC) announced today that a pilot clinical trial successfully met its primary endpoint of safety and tolerability, with the Company’s lead neuroprotective drug candidate davunetide, in patients with progressive supranuclear palsy (P... Continue reading →

Allons CEO presenting at BIO Investor Forum

(TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress on Wednesday, October 6 at the 9th Annual BIO Investor Forum in San Francisco attended by public and private equity investors, research analysts, investment bankers, and the pharma community. &... Continue reading →

Allons CEO presenting at Rodman and Renshaw Global Conference

VANCOUVER, B.C.— September 13, 2010— Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress on Tuesday, September 14 at the Rodman and Renshaw Annual Global Investment Conference in New York City. McCauley’s presentation wil... Continue reading →

Allon Therapeutics releases second quarter operating results

VANCOUVER, B.C.— August 11, 2010— Allon Therapeutics Inc. (TSX: NPC) today announced its unaudited operating results for the three months ended June 30, 2010. The Company also said it remains on course to develop its lead product davunetide as the first approved treatment for progressive supranuc... Continue reading →

← Older posts Newer posts →